Donor blood stem cells and T cells for Immune Tolerance

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Immune ToleranceDonor blood stem cells and T cells - Drug
Eligibility
18 - 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study if donor blood stem cells can help prevent kidney rejection after transplant.

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 24 months post-transplant

24 months post-transplant
Incidence of graft loss.
Incidence of rejection episodes requiring corticosteroid therapy
Reduction of dependence on immunosuppressive drugs to prevent graft rejection.

Trial Safety

Trial Design

1 Treatment Group

Immune tolerance after kidney transplant
1 of 1

Experimental Treatment

24 Total Participants · 1 Treatment Group

Primary Treatment: Donor blood stem cells and T cells · No Placebo Group · Phase < 1

Immune tolerance after kidney transplantExperimental Group · 2 Interventions: Donor blood stem cells and T cells, Immune tolerance after kidney transplant · Intervention Types: Drug, Procedure

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months post-transplant

Who is running the clinical trial?

Samuel StroberLead Sponsor
California Institute for Regenerative Medicine (CIRM)OTHER
59 Previous Clinical Trials
3,236 Total Patients Enrolled
Samuel Md Strober, MDStudy ChairStanford University
1 Previous Clinical Trials
25 Total Patients Enrolled
1 Trials studying Immune Tolerance
25 Patients Enrolled for Immune Tolerance

Eligibility Criteria

Age 18 - 65 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You are of reproductive potential and agree to practice a reliable form of contraception for at least 24 months posttransplant.
References